Related Experiment Video
Updated: Aug 6, 2026

Rapid Point-of-Care Assay of Enoxaparin Anticoagulant Efficacy in Whole Blood
Published on: October 12, 2012
Low-molecular-weight heparins for the prevention and treatment of venous thromboembolism
D L Ornstein1, Y G Hong-Dice, J R Papini
1Hematology/Oncology Flight, Wilford Hall U.S. Air Force Medical Center, Lackland Air Force Base, San Antonio, TX 78236, USA.
Abstract:
Low-molecular-weight heparins (LMWHs) are rapidly becoming the anticoagulants of choice for the prevention and treatment of venous thromboembolism. LMWHs are at least as safe and effective as unfractionated heparin, and they have the added advantage of improved pharmacokinetic and safety profiles. The result is that LMWHs are easier to use, provide a more predictable anticoagulant effect, and do not require routine laboratory monitoring in most circumstances. Currently, the LMWHs ardeparin, dalteparin, danaparoid, enoxaparin, and tinzaparin have Food and Drug Administration-approved indications in the United States. This paper reviews the clinical use and cost-effectiveness of the LMWHs for the prevention and treatment of venous thromboembolism.
Related Concept Videos
Anticoagulant Drugs: Low-Molecular-Weight Heparins
Venous Thrombosis I: Introduction
Venous Thrombosis II: Clinical Manifestations and Diagnostic Studies
Venous Thrombosis III: Interprofessional Care
Venous Thrombosis IV: Nursing Management
Pulmonary Embolism II: Diagnostic Studies and Interprofessional Care

